The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...

UnitedHealth Group has had a tumultuous year, marred by poor performance and controversy. Eli Lilly has thrived as it's taken ...

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

Eli Lilly ( LLY 1.19%) and Novo Nordisk ( NVO 2.44%) are two of the leading companies in the fast-growing GLP-1 weight loss ...

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

Lilly has a new pill, called orforglipron, it plans to launch next year. On Thursday, the company reported the results of a ...

The Huntsville Planning Commission voted to rezone 73.40 acres east of Greenbrier Road and north of Interstate 565 in ...

On December 16, Daiwa analyst Narumi Nakagiri upgraded Eli Lilly and Company (NYSE:LLY) to Buy from Neutral and set a $1,230 ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

Eli Lilly 's (NYSE: LLY) share price has soared over the past five years (up 530%). In fact, it's hard to find a single ...

Eli Lilly and Company (NYSE: LLY) is one of the most profitable NYSE stocks to buy right now. In a report released on ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...